Şunu aradınız:: do not cross (İngilizce - Maltaca)

do not
- tużax is- soluzzjoni fil- kunjetti jekk din tkun ta ’ kulur imdennes jew jekk ikun fiha materjal

do not:
tagĦmilx:

do not have
ma ghandiex

do not inject.
tinjettahiex.

insulin does not cross the placental barrier.
l-insulina ma taqsamx għal ġol-plaċenta.

dopamine does not cross the blood-brain barrier.
dopamine ma jaqsamx il-barriera ta’ bejn id-demm u l-moħħ.

certolizumab pegol does not cross-react with rodent tnf.
certolizumab pegol ma jagħmilx reazzjoni ma tnf fl-annimali ġerriema.

tasonermin did not cross the placenta or pass into necrotic tumour.
tasonermin ma jaqsamx il- plaċenta u lanqas tgħaddi għal ġo tumur nekrotiku.

does not cross at level with any railway or tramway track, or footpath.
ma taqsamx f’livell mal-ebda binarju ferrovjarju jew tat-tramm, jew mogħdija tar-riġel.

infliximab does not cross react with tnfα from species other than human and chimpanzees.
infliximab ma jagħmilx cross reaction ma’ tnfα minn speċi oħra barra mill-bniedem u x-ximpanżì.

carbidopa does not cross the blood-brain barrier at clinically relevant doses.
carbidopa ma jaqsamx il-barriera bejn id-demm u l-moħħ f’dożi klinikament rilevanti.

patients in the placebo arm did not cross-over to everolimus at the time of progression.
il-pazjenti fil-grupp tal-plaċebo ma qelbux għal everolimus waqt il-progressjoni.

fondaparinux does not cross-react with sera from patients with heparin-induced thrombocytopaenia.
fondaparinux ma jagħmilx cross reaction ma’ sera minn pazjenti bi tromboċitopenja indotta bl- eparina.

patients in the placebo + exemestane arm did not cross over to everolimus at the time of progression.
pazjenti fil-grupp mogħti plaċebo + exemestane ma għaddewx għal everolimus fil-perijodu ta’ progressjoni.

insulin does not cross the placental barrier. caution should be exercised when prescribing to pregnant women.
wieħed għandu joqgħod attent meta jikteb riċetta għal din il- mediċina għal nisa tqal.

a third isolate which carried a substitution at position 236 of rt was not cross-resistant to efavirenz.
it-tielet iżolat li kellu sostituzzjoni fil-pożizzjoni 236 ta’ rt ma kellux reżistenza msallba għal efavirenz.

patients with heparin induced thrombocytopenia fondaparinux does not bind to platelet factor 4 and does not cross-react with sera from patients with du
l- effikaċja u s- sigurta` ta ’ fondaparinux ma ot

pegvisomant is highly selective for the gh receptor, and does not cross-react with other cytokine receptors, including prolactin.
pegvisomant huwa selettiv ħafna għar-riċettur gh u ma jagħmilx reazzjoni ma’ riċetturi cytokine oħra, inkluż prolaktin.

of the 271 adult itp patients receiving romiplostim in the itp clinical programme one patient developed antibodies capable of neutralising the activity of romiplostim but these antibodies did not cross react with endogenous tpo.
mill- 271 pazjenti adulti b’ itp li rċevew romiplostim fil- programm kliniku ta ’ itp, pazjent wieħed żviluppa antikorpi li kapaċi jinnewtralizzaw l- attività ta ’ romiplostim iżda dawn l- antikorpi ma kellhomx reazzjoni ma ’ tpo endoġenu.

fondaparinux does not bind to platelet factor 4 and does not cross-react with sera from patients with heparin induced thrombocytopenia (hit) type ii.
fondaparinux ma jintrabatx mal-fattur 4 tal-plejtlets u ma jirreaġixxix mas-serum minn pazjenti b’ tromboċitopenja indotta bl- eparina (tie) tat-tip ii.